NEW YORK, August 9, 2016 /PRNewswire/ --
Sentiments over the Biotech industry have improved in previous weeks on confidence over drug pipelines and better global conditions. However, stocks are still down 13% this year. Today, Stock-Callers.com reviews four names to see how they have performed recently: Juno Therapeutics Inc. (NASDAQ: JUNO), Cellectar Biosciences Inc. (NASDAQ: CLRB), Titan Pharmaceuticals Inc. (NASDAQ: TTNP), and Rexahn Pharmaceuticals Inc. (NYSE MKT: RNN). Sign up today and download for free the research reports for the stocks covered today at:
Seattle, Washington headquartered Juno Therapeutics Inc.'s stock finished Monday's session at $32.69, climbing 3.91%. A total volume of 2.31 million shares traded, which was above their three months average volume of 2.05 million shares. Over the last month, the Company's shares have gained 17.55%. The stock is trading below its 50-day moving average by 11.68%. Moreover, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have a Relative Strength Index (RSI) of 49.36.
On August 4th, 2016, Juno Therapeutics announced that it has entered into an exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSK) and Eureka Therapeutics, Inc. for a novel, fully-human binding domain targeting B-cell maturation antigen (BCMA), along with binding domains against two additional undisclosed multiple myeloma targets to be used for the potential development and commercialization of chimeric antigen receptor (CAR) cell therapies for patients with multiple myeloma. The binding domains were developed under a collaboration agreement between Eureka Therapeutics and MSK. The parties expect the BCMA CAR to enter human testing as early as 1H2017.
On August 05th, 2016, research firm Maxim Group reiterated its 'Buy' rating on the Company's stock while it decreased the target price of the stock from $80 a share to $50 a share. JUNO complete research report is just a click away at:
Shares in Madison, Wisconsin headquartered Cellectar Biosciences Inc. ended yesterday's session 2.31% higher at $2.66 with a total volume of 54,850 shares traded. The stock has surged 82.19% in the previous three months. The Company's shares are trading 16.25% below their 50-day moving average. Moreover, shares of Cellectar Biosciences, which engages in the development of targeted phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer, have an RSI of 41.72.
On August 3rd, 2016, Cellectar Biosciences announced that it has received the second phase of a National Cancer Institute Fast-Track Small Business Innovation Research contract award in the amount of $2 million to support funding of a Phase 2 clinical study of the company's lead product candidate, CLR 131, for the potential treatment of hematologic malignancies, including multiple myeloma. The complimentary report on CLRB can be downloaded at:
On Monday, South San Francisco, California-based Titan Pharmaceuticals Inc.'s stock rose 1.38%, to close the day at $5.13 and with a total volume of 136,843 shares traded. The Company's shares have advanced 15.54% on an YTD basis. The stock is trading 6.88% above its 200-day moving average. Additionally, shares of Titan Pharmaceuticals, which develops proprietary therapeutics for the treatment of serious medical disorders in the US, have an RSI of 46.19.
On August 3rd, 2016, Titan Pharmaceuticals announced that it will host a live conference call at 4:15 p.m. EDT on August 9th, 2016 to discuss the company's financial results as of June 30th, 2016. The call will be hosted by Sunil Bhonsle, President and CEO; Kate Beebe, Ph.D., Executive Vice President and Chief Development Officer; Brian Crowley, Vice President of Finance; and Marc Rubin, M.D., Executive Chairman. Highlights of the second quarter will be included in a press release to be issued prior to the call. Sign up for your complimentary report on TTNP at:
Shares in Rockville, Maryland-based Rexahn Pharmaceuticals Inc. ended the day 0.62% lower at $0.27 with a total volume of 375,396 shares traded. The stock has gained 7.27% in the last one month. The Company's shares are trading above their 50-day moving average by 1.09%. Furthermore, shares of Rexahn Pharmaceuticals, which discovers, develops, and commercializes treatments for cancer, have an RSI of 59.22.
On August 8th, 2016, Rexahn Pharmaceuticals reported net loss of $1.8 million, or $0.01 per share, for the three months ended June 30th, 2016, compared to a net loss of $3.2 million, or $0.02 per share, for the three months ended June 30th, 2015. The company's research and development expenses were $2.2 million for the three months ended June 30th, 2016, compared to $3.2 million for the three months ended June 30th, 2015. Download the research report for free on RNN at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA